Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Susan M. Langan-Fahey"'
Publikováno v:
JNCI Journal of the National Cancer Institute. 85:806-812
Background The nonsteroidal anti-estrogen tamoxifen (TAM) is the front-line endocrine treatment for breast cancer, but disease recurrence is common. Treatment failure may occur because tumors become insensitive to TAM. Alternatively, resistance may o
Autor:
Susan M. Langan-Fahey, Mary K. Lababidi, V. Craig Jordan, Delinda A. Johnson, David F.C. Gibson, William H. Wolberg
Publikováno v:
Breast cancer research and treatment. 27(3)
The development of endometrial cancer is a potential risk during long-term tamoxifen therapy for breast cancer. In order to protect the uterus, progestin treatment has been proposed for these patients. However, within the 7,12-dimethylbenzanthracene-
Publikováno v:
Endocrinology. 132(6)
Previously, we demonstrated that the progestin components (19-nortestosterone derivatives) in oral contraceptives are able to stimulate human breast cancer cell proliferation via an estrogen receptor (ER)-mediated mechanism. We now examine RU486, an
Autor:
Susan M. Langan-Fahey, V. Craig Jordan, David F.C. Gibson, Ernest C. Borden, David Goldstein, Delinda A. Johnson
Publikováno v:
Breast cancer research and treatment. 25(2)
Tamoxifen is the endocrine treatment of choice for breast cancer. However, resistance to therapy and patient relapse inevitably occurs. In future treatment schedules, interferons could be administered with tamoxifen, in an attempt to prevent disease
Publikováno v:
Molecular endocrinology (Baltimore, Md.). 6(12)
The antiestrogen tamoxifen is used in the treatment of hormone-responsive breast cancer. However, therapeutic failure has frequently been observed in both patients and animal models after long term treatment. We have studied the effect of a point mut
Publikováno v:
Journal of the National Cancer Institute. 83(20)
Tamoxifen is used to treat selected patients at each stage of breast cancer. Although most clinical experience has been obtained with postmenopausal women, increasing numbers of premenopausal women will be treated with 5 or more years of adjuvant tam
Publikováno v:
Journal of the National Cancer Institute. 83(7)
A sustained release of tamoxifen, which produced decreasing serum levels of this drug (24 to 4 ng/mL) over 6 months, suppressed mammary tumorigenesis in virgin or once pregnant C3H/OUJ female mice. Tamoxifen was consistently more effective than early
Publikováno v:
European journal of cancerclinical oncology. 25(12)
The metabolism of tamoxifen in the human has been well established and may be important in the antiestrogenic activity of this agent. This study examines whether tamoxifen metabolism in the athymic mouse xenograft model is similar to tamoxifen metabo